---
layout: post
title: "Safety Considerations for Container Labels and Carton Labeling Design To Minimize Medication Errors; Guidance for Industry; Availability"
date: 2026-02-05 18:59:11 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-10699
original_published: 2022-05-18 00:00:00 +0000
significance: 8.00
---

# Safety Considerations for Container Labels and Carton Labeling Design To Minimize Medication Errors; Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** May 18, 2022 00:00 UTC
**Document Number:** 2022-10699

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors." The guidance focuses on safety aspects of the container label and carton labeling design for human prescription drug and biological products. The guidance provides sponsors of new drug applications (NDAs), biologics license applications (BLAs), abbreviated new drug applications (ANDAs), and prescription drugs marketed without an approved NDA or ANDA with a set of principles and recommendations for ensuring that critical elements of product container labels and carton labeling are designed to promote safe dispensing, administration, and use of the product. This guidance finalizes the draft guidance of the same title issued on April 24, 2013.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/05/18/2022-10699/safety-considerations-for-container-labels-and-carton-labeling-design-to-minimize-medication-errors)
- API: https://www.federalregister.gov/api/v1/documents/2022-10699

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
